|
|
Article: FeRx Raises $15M To Pay For Phase II/III Trial Of MTC-DOX.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
FeRx Inc. raised $15 million in a private placement that will fund its ongoing registration trial and other studies.
The company has raised $42 million since its inception in 1997, said FeRx President and CEO Jacqueline Johnson.
"It's primarily earmarked for completing our registration studies, and also it will pay for other clinical trials in other indications for the lead product," she said. "And, it will pay for introducing a second product into the clinic."
San Diego-based FeRx's lead product is MTC-DOX, a magnetic targeted carrier technology delivering the anticancer drug doxorubicin. It is in a Phase II/III trial for ...